Johnson & Johnson subsidiary Janssen

Johnson & Johnson's Janssen Pharmaceuticals unit – which manufactures drugs including the opioid Duragesic, a form of fentanyl – called its marketing activities “appropriate and responsible.” Endo did not respond to a request for comment. Prescription opioids are intended to treat pain, but the outbreak ...

Dominic Caruso, Johnson & Johnson's longest-serving CFO in the company's 132-year history, will retire in September. He came to J&J in 1999 through the ... will replace Caruso on July 1. Wolk has been with J&J for 19 years and was once CFO of the Janssen Pharmaceutical Companies. Release ...

Mr Wolk has been with Johnson & Johnson for 19 years and has served on the finance leadership team, reporting directly to Mr Caruso since 2014. Previously, he was VP, finance and CFO of the Janssen Pharmaceutical Companies of Johnson & Johnson and was a member of the Janssen Group ...

Wolk has worked with Johnson & Johnson for 19 years, and has directly served under Caruso since 2014. Prior to joining J&J, Wolk acted as CFO of J&J's Janssen Pharmaceutical companies and was a member of Janssen's group operating committee. “Joe is a strong, collaborative, credo-based leader ...

Mr. Wolk has been with Johnson & Johnson for 19 years and has served on the Finance Leadership team, reporting directly to Mr. Caruso since 2014. Previously, he was Vice President, Finance and CFO of the Janssen Pharmaceutical Companies of Johnson & Johnson and was a member of the Janssen ...

Janssen Pharmaceutica, which is part of US healthcare giant Johnson & Johnson (NYSE: JNJ), plans to increase production of its Sirturo (bedaquiline) –an anti-tuberculosis drug – in Russia, at the capacities of a local drugmaker Pharmstandard, according to recent statements of the companies, reportsThe ...

A new analysis from the CANVAS study showed patients with type 2 diabetes (T2D) treated with Johnson & Johnson (JNJ -0.6%) unit Janssen Pharmaceuticals' INVOKANA (canagliflozin) experienced significantly less risk of cardiovascular (CV) death or hospitalization for heart failure (HHF). The data were ...

Biocartis has struck a deal with Johnson & Johnson to expand its presence in the U.S. J&J's Janssen is transferring a respiratory assay panel and some of the staff who worked on it to Biocartis, while also making space available for the company at its site in Raritan, New Jersey. Mechelen, Belgium-based ...

Johnson & Johnson Innovation, the Janssen Pharmaceutical Companies of Johnson & Johnson and A*STAR initiated the World Without Disease Grant Call to support life science innovation in Singapore and advance the discovery and development of solutions to prevent, intercept and cure diseases.

The next-gen biologic from Johnson & Johnson's Janssen began airing its first DTC campaign two weeks ago, joining two other new-age drugs already tearing up the psoriasis market and grabbing TV time. Both Novartis' Cosentyx and Eli Lilly's Taltz have spent big on TV to establish their brands. Novartis ...

Johnson & Johnson Innovation, the Janssen Pharmaceutical Companies of Johnson & Johnson and A*STAR initiated the World Without Disease Grant Call to support life science innovation in Singapore and advance the discovery and development of solutions to prevent, intercept and cure diseases.

Sierra Oncology and Janssen Sign Supply Agreement for Prostate Cancer Study. Paul Quintaro , Benzinga Staff Writer {{following ? "Following" : "Follow"}}. February 27, 2018 7:42am Comments. Share: ...

Just after New Year's, in an announcement that was easy to overlook in the post-holiday haze, Johnson & Johnson's Janssen Pharmaceutical celebrated an historic FDA approval. The agency cleared new label language for the company's 9-year-old schizophrenia treatment, Invega Sustenna, stating that ...

The U.S. Food and Drug Administration today approved Erleada (apalutamide) for the treatment of patients with prostate cancer that has not spread (non-metastatic), but that continues to grow despite treatment with hormone therapy (castration-resistant). This is the first FDA-approved treatment for ...

Theravance Biopharma Inc. (NASDAQ: TBPH) said Wednesday that Johnson & Johnson's (NYSE: JNJ) Janssen Biotech group will pay $200 million when mid-stage work across two studies in ulcerative colitis and Crohn's disease are completed and another $700 million in development and commercial ...